Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits

Stephen M. Stahl

Chapter 9 - Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits

from Section 3 - Neurobiology

Published online by Cambridge University Press: 19 October 2021

Stephen M. Stahl

Edited by

Katherine D. Warburton and

Stephen M. Stahl

Show author details

Katherine D. Warburton: Affiliation:
University of California, Davis
Stephen M. Stahl: Affiliation:
University of California, San Diego

Book contents

Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Type: Chapter
Information: Violence in Psychiatry , pp. 73 - 80

DOI: https://doi.org/10.1017/9781316135839 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Warburton, K. The new mission of forensic mental health systems: managing violence as a medial syndrome in an environment that balances treatment and safety. CNS Spectr. 2014 Oct; 19(5): 368–373. DOI: 10.1017/S109285291400025X.Google Scholar

Stahl, SM, Morrissette, DA, Cummings, M, et al. The California Department of State Hospitals Violence Assessment and Treatment (CAL-VAT) guidelines. CNS Spectr. 2014; 19(5): 357–365. DOI: 10.1017/S109285291400376.Google Scholar

Stahl, SM, Morrissette, DA, Citrome, L, et al. “Metaguidelines” for the management of patients with schizophrenia. CNS Spectr. 2013; 18(3): 150–162.Google Scholar

Correll, CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry. 2010; 25(Suppl. 2): S12–21.Google Scholar

Davis, JM, Chen, N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol. 2004; 24(2): 192–208.Google Scholar

Krakowski, MI, Kunz, M, Czobor, P, Volavka, J. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp. Community Psychiatry. 1993; 44(7): 640–644.Google Scholar

Comai, S, Tau, M, Gobbi, G. The psychopharmacology of aggressive behavior: a translational approach: part 1:neurobiology. J. Clin. Psychopharmacol. 2012; 32(1): 83–94.Google Scholar

Comai, S, Tau, M, Pavlovic, Z, Gobbi, G. The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J. Clin. Psychopharmacol. 2012; 32(2): 237–260.Google Scholar

Citrome, L, Volavka, J. The psychopharmacology of violence: making sensible decisions. CNS Spectr. 2014 Oct; 19(5): 411–418. DOI: 10.1017/S109285291400054.Google Scholar

Volavka, J, Czobor, P, Citrome, L, Van Dorn, RA. Effectiveness of antipsychotic drugs against hostility with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectr. 2014; 0(5): 374–381. DOI: 10.1017/S1092852913000849.Google Scholar

Meyer, JM. A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr. 2014 Oct; 0(5): 432–438. DOI: 10.1017/S10928514000236.Google Scholar

Morrissette, DA, Stahl, SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr. 2014; 19(5). DOI: 10.1017/S1092852914000388.Google Scholar

Stahl, SM. Emerging guidelines for the use of antipsychotic polypharmacy. Rev. Psiquiatr. Salud. Ment. 2013; 6(3): 97–100.Google Scholar

Stahl, SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr. Scand. 2012; 125(5): 349–351.Google Scholar

Morrissette, DA, Stahl, SM. Should high dose or very long-term antipsychotic monotherapy be considered before antipsychotic polypharmacy? In Ritsner, MS, ed. Polypharmacy in Psychiatric Practice, Volume 1: Multiple Medication Use Strategies. Heidelberg: Springer; 2013: 107–125.Google Scholar

Volavka, J, Citrome, L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr. Bull. 2011; 37(5): 921–929.Google Scholar

Volavka, J, Citrome, L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int. J. Clin. Pract. 2008; 62(8): 1237–1245.Google Scholar

Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine’s antiaggressive effects. Int. J. Neuropsychopharmacol. 2012; 15(9): 1351–1371.Google Scholar

Stilwell, EN, Yates, SE, Brahm, NC. Violence among persons diagnosed with schizophrenia: how pharmacists can help. Res. Social Adm. Pharm. 2011; 7(4): 421–429.Google Scholar

Swanson, JW, Swartz, MS, Van Dorn, RA, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br. J .Psychiatry. 2008; 193(1): 37–43.Google Scholar

Volavka, J, Czobor, P, Nolan, K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychopharmacol. 2004; 24(2): 225–228.Google Scholar

Topiwala, A, Fazel, S. The pharmacological management of violence in schizophrenia: a structured review. Expert Rev. Neurother. 2011; 11(1): 53–63.Google Scholar

Bourget, D, Labelle, A. Managing pathologic aggression in people with psychotic disorders. J. Psychiatry Neurosci. 2012; 37(2): E3–4.Google Scholar

Citrome, L, Volavka, J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs. 2011; 25(12): 1009–1021.CrossRef Google Scholar PubMed

Roh, D, Chang, JG, Kim, CH, et al. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Aust. N. Z. J. Psychiatry. 2014; 48(1): 52–60.Google Scholar

Barnes, TR, Paton, C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011; 25(5): 383–399.Google Scholar

Fleischhacker, WW, Uchida, H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. Jul; 17(7): 1083–1093.Google Scholar

Fujita, J, Nishida, A, Sakata, M, Noda, T, Ito, H. Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia. Psychiatry Clin. Neurosci. 2013; 67(5): 345–351.Google Scholar

Gallego, JA, Bonetti, J, Zhang, J, Kane, JM, Correll, CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr. Res. 2012; 138(1): 18–28.Google Scholar

Lochmann van Bennekom, MW, Gijsman, HJ, Zitman, FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J. Psychopharmacol. 2013; 27(4): 327–336.Google Scholar

Langle, G, Steinert, T, Weiser, P, et al. Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr. Scand. 2012; 125(5): 372–381.Google Scholar

Essock, SM, Schooler, NR, Stroup, TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am. J. Psychiatry. 2011; 168(7): 702–708.Google Scholar

Suzuki, T, Uchida, H, Tanaka, KF, et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int. J. Neuropsychopharmacol. 2004; 7(2): 133–142.Google Scholar

Stahl, SM, Grady, MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr. Med .Chem. 2004; 11(3): 313–327.Google Scholar

Aggarwal, NK, Sernyak, MJ, Rosenheck, RA. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. J. Clin. Psychopharmacol. 2012; 32(3): 323–328.Google Scholar

Stahl, SM. The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. CNS Spectr. 2013; 18(2): 65–68.CrossRef Google Scholar PubMed

Singh, JP, Serper, M, Reinharth, J, Fazel, S. Structured assessment of violence risk in schizophrenia and other psychiatric disorders: a systematic review of the validity, reliability, and item content of 10 available instruments. Schizophr. Bull. 2011; 37(5): 899–912.Google Scholar

Nolan, KA, Czobor, P, Roy, BB, et al. Characteristics of assaultive behavior among psychiatric inpatients. Psychiatr. Serv. 2003; 54(7): 1012–1016.CrossRef Google Scholar PubMed

Abderhalden, C, Needham, I, Dassen, T, et al. Predicting inpatient violence using an extended version of the Brøset-Violence-Checklist: instrument development and clinical application. BMC Psychiatry. 2006; 6: 17.Google Scholar

Quanbeck, CD, McDermott, BE, Lam, J, et al. Categorization of aggressive acts committed by chronically assaultive state hospital patients. Psychiatr. Serv. 2007; 58(4): 521–528.Google Scholar

McDermott, BE, Holoyda, BJ. Assessment of aggression in inpatient settings. CNS Spectr. 2014 Oct; 0(5): 425–431. DOI: 10.1017/S1092852914000224.Google Scholar

Monahan, J, Skeem, JL. The evolution of violence risk assessment. CNS Spectr. 2014 Oct; 0(5): 419–424. DOI: 10.1017/S1092852914000145.Google Scholar

Stahl, SM, Morrissette, DA. Stahl’s Illustrated: Violence: Neural Circuits, Genetics and Treatment. Cambridge, UK: Cambridge University Press; 2014.Google Scholar

Wehring, HJ, Carpenter, WT. Violence and schizophrenia. Schizophr. Bull. 2011; 37(5): 877–878.CrossRef Google Scholar PubMed

Song, H, Min, SK. Aggressive behavior model in schizophrenic patients. Psychiatry Res. 2009; 167(1–2): 58–65.Google Scholar

Serper, M, Beech, DR, Harvey, PD, Dill, C. Neuropsychological and symptom predictors of aggression on the psychiatric inpatient service. J. Clin. Exp. Neuropsychol. 2008; 30(6): 700–709.Google Scholar

Stahl, SM. Stahl’s Essential Psychopharmacology. 4th edn. New York: Cambridge University Press; 2013.Google Scholar

Siever, LJ. Neurobiology of aggression and violence. Am. J. Psychiatry. 2008; 165(4): 429–442.Google Scholar

Nord, M, Farde, L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci. Ther. 2011; 17(2): 97–103.Google Scholar

Mauri, MC, Volonteri, LS, Colasanti, A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin. Pharmacokinet. 2007; 46(5): 359–388.Google Scholar

Coccaro, EF, Sripada, CS, Yanowitch, RN, Phan, KL. Corticolimbic function in impulsive aggressive behavior. Biol. Psychiatry. 2011; 69(12): 1153–1159.Google Scholar

Coccaro, EF, McCloskey, MS, Fitzgerald, DA, Phan, KL. Amygdala and orbitofrontal reactivity to social threat in individuals with impulsive aggression. Biol. Psychiatry. 2007; 62(2): 168–178.CrossRef Google Scholar PubMed

Hoptman, MJ, Antonius, D. Neuroimaging correlates of aggression in schizophrenia: an update. Curr. Opin. Psychiatry. 2011; 24(2): 100–106.Google Scholar

De Sanctis, P, Foxe, JJ, Czobor, P, et al. Early sensory-perceptual processing deficits for affectively valenced inputs are more pronounced in schizophrenia patients with a history of violence than in their non-violent peers. Soc. Cogn. Affect Neurosci. 2013; 8(6): 678–687.Google Scholar

Kumari, V, Barkataki, I, Goswami, S, et al. Dysfunctional, but not functional, impulsivity is associated with a history of seriously violent behaviour and reduced orbitofrontal and hippocampal volumes in schizophrenia. Psychiatry Res. 2009; 173(1): 39–44.Google Scholar

Coccaro, EF. Intermittent explosive disorder as a disorder of impulsive aggression for DSM-5. Am. J. Psychiatry. 2012; 169(6): 577–588.Google Scholar

Haller, J. The neurobiology of abnormal manifestations of aggression—a review of hypothalamic mechanisms in cats, rodents, and humans. Brain Res. Bull. 2013; 93: 97–109.Google Scholar

Kumari, V, Aasen, I, Taylor, P, et al. Neural dysfunction and violence in schizophrenia: an fMRI investigation. Schizophr. Res. 2006; 84(1): 144–164.Google Scholar

Krakowski, MI, Czobor, P, Nolan, KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J. Clin. Psychopharmacol. 2008; 28(5): 485–493.Google Scholar

Krakowski, MI, Czobor, P. Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial. J. Clin. Psychiatry. 2012; 73(1): 74–80.Google Scholar

Elie, D, Poirier, M, Chianetta, J, et al. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J. Psychopharmacol. 2010; 24(7): 1037–1044.Google Scholar

Singh, JP, Volavka, J, Czobor, P, Van Dorn, RA. A metaanalysis of the Val158Met COMT polymorphism and violent behavior in schizophrenia. PloS One. 2012; 7(8): e43423.Google Scholar

Pavlov, KA, Chistiakov, DA, Chekhonin, VP. Genetic determinants of aggression and impulsivity in humans. J. Appl. Genet. 2012; 53(1): 61–82.Google Scholar

Rosell, DR, Thompson, JL, Slifstein, M, et al. Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients. Biol. Psychiatry. 2010; 67(12): 1154–1162.Google Scholar

Winstanley, CA, Theobald, DE, Dalley, JW, Glennon, JC, Robbins, TW. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology (Berl). 2004; 176(3–4): 376–385.Google Scholar